top of page
vinnytsia-ukraine-december-28-2017-offset-printing-process-ready-newspaper-print-mashine.j

DISCOVER OUR PIONEERING CONTRIBUTIONS TO ONCOLOGY THROUGH PRESTIGIOUS JOURNALS AND PLATFORMS LIKE ASCO, ESMO, AND SABCS. ELEVATE YOUR INSIGHTS WITH OUR CUTTING-EDGE CLINICAL TRIAL PUBLICATIONS.

EMPOWERING PROGRESS: ONCOLOGY CLINICAL TRIALS SPOTLIGHT

PUBLICATIONS

Publications

THE ULTIMATE GOAL OF MEDSIR PROJECTS IS THE PUBLICATION OF ITS STUDY RESULTS, WHETHER IN PEER-REVIEWED JOURNALS OR AT A NUMBER OF NATIONAL AND INTERNATIONAL CONFERENCES IN THE FORM OF ABSTRACTS, POSTERS, OR ORAL PRESENTATIONS.

STUDY

OFFICIAL TITLE

DISEASE

JOURNAL/
CONGRESS

YEAR

DOWNLOAD

Publications

DEBBRAH

Trastuzumab Deruxtecan in Patients with Central Nervous System Involvement from HER2-Positive Breast Cancer: The DEBBRAH Trial

BREAST

(Journal) Neuro-Oncology

2023

DEBBRAH
Publications

I3LUNG

The EU-funded I3LUNG Project: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy

LUNG

(Journal) Clinical Lung Cancer

2023

I3LUNG
Publications

PHERGAIN

3-year invasive disease-free survival (iDFS) of the strategy-based, randomized phase II PHERGain trial evaluating chemotherapy (CT) de-escalation in human epidermal growth factor receptor 2-positive (HER2[+]) early breast cancer (EBC) 

BREAST

ASCO

2023

PHERGAIN
Publications

DEBBRAH

Trastuzumab Deruxtecan in patients with HER2[+] or HER2-Low Advanced
Breast Cancer and Pathologically Confirmed Leptomeningeal Carcinomatosis:
Results from Cohort 5 of the DEBBRAH Study

BREAST

SABCS

2023

DEBBRAH
Publications

LUPER

Lurbinectedin In Combination With Pembrolizumab In Relapsed Small Cell Lung Cancer (SCLC): The Phase 1/2 LUPER Study

LUNG

ESMO

2023

LUPER
Publications

ORPHEUS

A phase 2 study of the efficacy and safety of INCMGA00012 in advanced penile squamous cell carcinoma (PSqCC): ORPHEUS

PENIS

ASCO

2023

ORPHEUS
Publications

PHERGAIN (sub-study)

Validation of a genomic assay in early-stage HER2+ breast cancer treated with trastuzumab and pertuzumab (HP): a correlative analysis from PHERGain phase II trial

BREAST

ESMO

2023

PHERGAIN (sub-study)
Publications

ATRACTIB

Efficacy and safety of first-line atezolizumab, bevacizumab, and paclitaxel in
patients with advanced triple-negative breast cancer (aTNBC):
the ATRACTIB phase II trial.

BREAST

SABCS

2023

ATRACTIB
Publications

PARSIFAL

Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial 

BREAST

(Journal) The Oncologist

2023

PARSIFAL
Publications

BIOPER

Palbociclib Rechallenge for Hormone Receptor–Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial

BREAST

(Journal) Clinical Cancer Research

2023

BIOPER
Publications

PARSIFAL

ctDNA-based DNADX in hormone receptor-positive and HER2-negative (HR+/HER2-) advanced breast cancer following
endocrine therapy and CDK4/6 inhibition: a correlative analysis from the randomized phase 2 PARSIFAL trial

BREAST

SABCS

2023

PARSIFAL
Publications

DEBBRAH

Trastuzumab Deruxtecan in patients with HER2[+] or HER2-Low
Advanced Breast Cancer and Pathologically Confirmed
Leptomeningeal Carcinomatosis: Results from Cohort 5 of the
DEBBRAH Study

BREAST

SABCS

2023

DEBBRAH
Publications

Other MEDSIR related articles

home_fondo_cuadritos2.jpg
"
WE TURN THE BEST CLINICAL RESEARCH IDEAS INTO A BRIGHTER FUTURE FOR CANCER PATIENTS.
bottom of page